Osteoporosis Drugs Market to be Valued USD 20.17 Billion by 2026
Rising prevalence of
osteoporosis and surge in geriatric population to drive the global osteoporosis
drugs market.
According
to TechSci Research report, “Global
Osteoporosis Drugs Market By Drug Class
(Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid
Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By
Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By
Route of Administration (Oral, Injectable, and Others), By Gender (Female,
Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region, Forecast & Opportunities, 2026”, the market is anticipated to grow at a healthy CAGR during
the forecast period. The key factors propelling the growth of the global
osteoporosis drugs market include rising prevalence of osteoporosis and surge
in geriatric population around the world as they pose high susceptibility for
osteoporosis. Growing adoption of sedentary lifestyle is also impacting bone
health and thus, there is a rise in demand for osteoporosis drugs. Additionally,
the increase in osteoporosis cases due to menopause in women is acting as a
major growth driver for this market. In men, lifestyle associated factors such
as smoking and alcohol abuse are found to promote osteoporosis. This is further
expected to augment the global osteoporosis drugs market through 2026.
Moreover, increasing investment in R&D activities
for the development of advanced new drug classes is also fueling the market
growth. The wide range of pipeline drugs for approval in clinical trials are
also expected to provide lucrative growth opportunities for osteoporosis drug
manufacturers. However, the market is also prone to some challenges. Several
side effects of osteoporosis drugs such as heartburn, nausea, irritable bowel
syndrome and ulcers in the stomach are likely to hamper the market growth.
Furthermore, the time-taking drug approval process is also anticipated to
restrain the global osteoporosis drugs market growth.
Browse 182 Figures spread through 110 Pages and an in-depth TOC on "Global Osteoporosis Drugs
Market"
https://www.techsciresearch.com/report/osteoporosis-drugs-market/5081.html
Global osteoporosis drugs market can be
segmented based on disease type, drug class, route of
administration, gender, distribution channel and region. Based on drug class,
the market can be segmented into bisphosphonates, Selective Estrogen Inhibitors
Modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand
inhibitors, and others. Among them, parathyroid hormone therapy are expected to
register highest CAGR during the forecast period as they are increasingly being used to treat osteoporosis and have lesser
side effects.
Based on route of administration, global osteoporosis
drugs market can be segmented into oral, injectable, and others. Among them, the
oral segment accounted for largest market share in 2020 owing to abundant
availability of medications which are taken orally. However, the injectable
segment is anticipated to witness fastest growth through 2026 owing to growing
need for drugs that exhibit improved bioavailability rapid mode of action.
Major companies operating in global
osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva
Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline
Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company,
Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda
Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion
Pharmaceuticals Plc., among others. The companies are undergoing new product
development and collaborative research initiatives to increase their share in
global osteoporosis drugs market.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5081
Customers
can also request for 10% free customization on this report.
“North
America dominated the global osteoporosis drugs market in 2020 and is expected
to hold its dominance through 2026 owing to rising prevalence of osteoporosis and
easy availability of osteoporosis drugs in the region. However, Asia Pacific is
anticipated to undergo fastest growth during the forecast period due to
thriving life science industry and growing awareness about the benefits of osteoporosis
drugs,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Global Osteoporosis Drugs Market By Drug Class
(Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid
Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By
Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By
Route of Administration (Oral, Injectable, and Others), By Gender (Female,
Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of global osteoporosis
drugs market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in global osteoporosis drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]